Jessie L.-S. Au, Ph.D.
Professor of Research
Phone (405) 271-6593 x47272
Fax (405) 271-7505
Office CPB 303
I am a pharmaceutical scientist with strong interests in teaching as well as product development.
My first academic position was at The Ohio State University where I was a distinguished university professor and trained 36 Ph.D. and 5 M.Sc. in pharmaceutical sciences. This experience has led to my opinion that a new, cross-fertilization approach is needed to train drug development scientists who can translate the explosive growth in biomedical scientific knowledge into efficacious and cost-efficiently treatments. This, in turn, requires bringing professors in diverse disciplines (biological, physical, computational sciences) to share the training of graduate students so that the future scientists will have the unique combination of expertise that has proven elusive thus far, in part due to the silo structures in academic programs. I left my tenured professor position in 2013, became non-tenured professors at several universities, and joined Optimum Therapeutics LLC as its Chief Scientific Officer. This arrangement, albeit unorthodox, has provided the opportunity to pioneer this new educational approach and to develop a graduate program to focus on overcoming the deficiencies in preclinical-to-clinical translation. Since Fall 2015, I accepted endowed professorships at two university (part-time basis). In 2016, I founded Institute of Quantitative Systems Pharmacology (IQSP), a nonprofit organization with the goal of stimulating and facilitating inter-institutional collaborations. I initiated the QSP program at University of Oklahoma (OUHSC) in Fall 2015 and at Taipei Medical University (TMU) in 2016. The OUHSC program has since enrolled 7 predoctoral and 3 post-doctoral students. TMU hired a new tenure-track faculty (Dr. Chien-Ming Hsieh) who worked with me at IQSP from August to September, 2017. Professor Hsieh and I are co-chairing a QSP symposium at TMU in April 2018; the purpose is to introduce the concept of QSP and the new FDA requirements on using modeling-based approaches to assist and facilitate drug development efforts in Taiwan.
My two research goals are to develop new concepts in translational research and to develop effective treatments. I have developed a new standard-of-care for non-muscle invading bladder cancer, and am working on bringing two NIH-supported discoveries to the market. Over the last 10 years I have extended my work in drug delivery systems to other diseases. An example is the current project, in which we propose to use nanotechnology as a physicochemical means to lower the elevated blood apoB level caused by aging-related disruptions of cholesterol metabolism and lipoprotein homeostasis that are linked to two major aging-related diseases in the US (age-related macular degeneration, cardiovascular diseases).
Publications & Presentations
- 11. Yeung B Z, Lu Z, Wientjes G M, Au J. High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA. The AAPS journal. 2015; 17 : 1475-82
12. Wang J, Lu Z, Wang J, Cui M, Yeung B Z, Cole D J, Wientjes M G, Au J. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. Journal of controlled release : official journal of the Controlled Release Society. 2015; 216 : 103-10
13. Au J, Lu Z, Wientjes M G. Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. The AAPS journal. 2015; 17 : 1065-79
14. You J, Yang H, Lai Y, Simon L, Au J, Burkart A L. ARID2, p110α, p53, and β-catenin protein expression in hepatocellular carcinoma and clinicopathologic implications. Human pathology. 2015; 46 : 1068-77
15. Cui M, Au J, Wientjes M G, O'Donnell M A, Loughlin K R, Lu Z. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts. The Journal of urology. 2015; 194 : 230-7
- 1. Experimental and computational studies to identify optimal conditions for immune-cytotoxic combination therapy. State Agency. Start Date: 2022. End Date: 2022.
Awards and Honors
- 1. Taipei Medical University. Endowed Chair in Systems Pharmacology. Date: 2016.
2. American Association of Pharmaceutical Scientists. Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism. Date: 2004.
3. American Association for the Advancement of Science. Fellow. Date: 1999.
4. American Association of Pharmaceutical Scientists. Fellow. Date: 1992.
5. NIH. MERIT Award. Date: 1992.
- 1. Degree: Postdoctoral Fellowship. Dept of Experimental Therapeutics, Roswell Park Memorial Institute. Date: 1983.
2. Degree: Ph D. Dept Pharmaceutical Chemistry, University of California. Date: 1980.
3. Degree: PharmD. School of Pharmacy, University of California. Date: 1972.
- 1. Director. University. Deputy Director, OSU CCC. Date: 1994.
2. Director. University. Director of Translational Research, OSU CCC. Date: 1993.
External Connections and Partnerships